#BEGIN_DRUGCARD DB03994

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
141-43-5

# ChEBI_ID:
16000

# Chemical_Formula:
C2H7NO

# Chemical_IUPAC_Name:
2-aminoethan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin. It is used as a surfactant, fluorimetric reagent, and to remove CO2 and H2S from natural gas and other gases. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.31

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+006 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ethanolamine

# HET_ID:
ETA

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C2H7NO/c3-1-2-4/h4H,1-3H2

# InChI_Key:
InChIKey=HZAXFHJVJLSVMW-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00189

# KEGG_Drug_ID:
D05074

# LIMS_Drug_ID:
3994

# Mechanism_Of_Action:
Not Available

# Melting_Point:
10.5 Â°C

# Molecular_Weight_Avg:
61.0831

# Molecular_Weight_Mono:
61.052763851

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1NG8

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.5

# Predicted_LogS:
1.14

# Predicted_Water_Solubility:
8.49e+02 g/l

# Primary_Accession_No:
DB03994

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
700

# PubChem_Substance_ID:
46508846

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01366

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NCCO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:50 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
9.5

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AF175678

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
nspA

# Drug_Target_1_Gene_Sequence:
>525 bp
ATGAAAAAAGCACTTGCCACACTGATTGCCCTCGCTCTCCCGGCCGCCGCACTGGCGGAA
GGCGCATCCGGCTTTTACGTCCAAGCCGATGCCGCACACGCAAAAGCCTCAAGCTCTTTA
GGTTCTGCCAAAGGCTTCAGCCCGCGCATCTCCGCAGGCTACCGCATCAACGACCTCCGC
TTCGCCGTCGATTACACGCGCTACAAAAACTATAAAGCCCCATCCACCGATTTCAAACTT
TACAGCATCGGCGCGTCCGCCATTTACGACTTCGACACCCAATCGCCCGTCAAACCGTAT
CTCGGCGCGCGCTTGAGCCTCAACCGCGCCTCCGTCGACTTGGGCGGCAGCGACAGCTTC
AGCCAAACCTCCATCGGCCTCGGCGTATTGACGGGCGTAAGCTATGCCGTTACCCCGAAT
GTCGATTTGGATGCCGGCTACCGCTACAACTACATCGGCAAAGTCAACACTGTCAAAAAC
GTCCGTTCCGGCGAACTGTCCGCCGGTGTGCGCGTCAAATTCTGA

# Drug_Target_1_General_Function:
Involved in porin activity

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4778

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
18397

# Drug_Target_1_Name:
Surface protein A

# Drug_Target_1_Number_of_Residues:
174

# Drug_Target_1_PDB_ID:
1P4T

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02462	Opacity

# Drug_Target_1_Protein_Sequence:
>Surface protein A
MKKALATLIALALPAAALAEGASGFYVQADAAHAKASSSLGSAKGFSPRISAGYRINDLR
FAVDYTRYKNYKAPSTDFKLYSIGASAIYDFDTQSPVKPYLGARLSLNRASVDLGGSDSF
SQTSIGLGVLTGVSYAVTPNVDLDAGYRYNYIGKVNTVKNVRSGELSAGVRVKF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q9RP17

# Drug_Target_1_SwissProt_Name:
Q9RP17_NEIME

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
10.02

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
Not Available

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ANXA3

# Drug_Target_2_GenBank_ID_Gene:
M20560

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ANXA3

# Drug_Target_2_Gene_Sequence:
>972 bp
ATGGCATCTATCTGGGTTGGACACCGAGGAACAGTAAGAGATTATCCAGACTTTAGCCCA
TCAGTGGATGCTGAAGCTATTCAGAAAGCAATCAGAGGAATTGGAACTGATGAGAAAATG
CTCATCAGCATTCTGACTGAGAGGTCAAATGCACAGCGGCAGCTGATTGTTAAGGAATAT
CAAGCAGCATATGGAAAGGAGCTGAAAGATGACTTGAAGGGTGATCTCTCTGGCCACTTT
GAGCATCTCATGGTGGCCCTAGTGACTCCACCAGCAGTCTTTGATGCAAAGCAGCTAAAG
AAATCCATGAAGGGCGCGGGAACAAACGAAGATGCCTTGATTGAAATCTTAACTACCAGG
ACAAGCAGGCAAATGAAGGATATCTCTCAAGCCTATTATACAGTATACAAGAAGAGTCTT
GGAGATGACATTAGTTCCGAAACATCTGGTGACTTCCGGAAAGCTCTGTTGACTTTGGCA
GATGGCAGAAGAGATGAAAGTCTGAAAGTGGATGAGCATCTGGCCAAACAAGATGCCCAG
ATTCTCTATAAAGCTGGTGAGAACAGATGGGGCACGGATGAAGACAAATTCACTGAGATC
CTGTGTTTAAGGAGCTTTCCTCAATTAAAACTAACATTTGATGAATACAGAAATATCAGC
CAAAAGGACATTGTGGACAGCATAAAAGGAGAATTATCTGGGCATTTTGAAGACTTACTG
TTGGCCATAGTTAATTGTGTGAGGAACACGCCGGCCTTTTTAGCCGAAAGACTGCATCGA
GCCTTGAAGGGTATTGGAACTGATGAGTTTACTCTGAACCGAATAATGGTGTCCAGATCA
GAAATTGACCTTTTGGACATTCGAACAGAGTTCAAGAAGCATTATGGCTATTCCCTATAT
TCAGCAATTAAATCGGATACTTCTGGAGACTATGAAATCACACTCTTAAAAATCTGTGGT
GGAGATGACTGA

# Drug_Target_2_General_Function:
Involved in calcium ion binding

# Drug_Target_2_General_References:
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
1830024	Tait JF, Frankenberry DA, Miao CH, Killary AM, Adler DA, Disteche CM: Chromosomal localization of the human annexin III (ANX3) gene. Genomics. 1991 Jun;10(2):441-8.
2138632	Ernst JD, Hoye E, Blackwood RA, Jaye D: Purification and characterization of an abundant cytosolic protein from human neutrophils that promotes Ca2(+)-dependent aggregation of isolated specific granules. J Clin Invest. 1990 Apr;85(4):1065-71.
2159184	Ross TS, Tait JF, Majerus PW: Identity of inositol 1,2-cyclic phosphate 2-phosphohydrolase with lipocortin III. Science. 1990 May 4;248(4955):605-7.
2968983	Pepinsky RB, Tizard R, Mattaliano RJ, Sinclair LK, Miller GT, Browning JL, Chow EP, Burne C, Huang KS, Pratt D, et al.: Five distinct calcium and phospholipid binding proteins share homology with lipocortin I. J Biol Chem. 1988 Aug 5;263(22):10799-811.
2975506	Tait JF, Sakata M, McMullen BA, Miao CH, Funakoshi T, Hendrickson LE, Fujikawa K: Placental anticoagulant proteins: isolation and comparative characterization four members of the lipocortin family. Biochemistry. 1988 Aug 23;27(17):6268-76.
8276419	Tait JF, Smith C, Xu L, Cookson BT: Structure and polymorphisms of the human annexin III (ANX3) gene. Genomics. 1993 Oct;18(1):79-86.
8639653	Favier-Perron B, Lewit-Bentley A, Russo-Marie F: The high-resolution crystal structure of human annexin III shows subtle differences with annexin V. Biochemistry. 1996 Feb 13;35(6):1740-4.

# Drug_Target_2_HGNC_ID:
HGNC:541

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
5483

# Drug_Target_2_Locus:
4q13-q22

# Drug_Target_2_Molecular_Weight:
36376

# Drug_Target_2_Name:
Annexin A3

# Drug_Target_2_Number_of_Residues:
323

# Drug_Target_2_PDB_ID:
1AII

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00191	Annexin

# Drug_Target_2_Protein_Sequence:
>Annexin A3
MASIWVGHRGTVRDYPDFSPSVDAEAIQKAIRGIGTDEKMLISILTERSNAQRQLIVKEY
QAAYGKELKDDLKGDLSGHFEHLMVALVTPPAVFDAKQLKKSMKGAGTNEDALIEILTTR
TSRQMKDISQAYYTVYKKSLGDDISSETSGDFRKALLTLADGRRDESLKVDEHLAKQDAQ
ILYKAGENRWGTDEDKFTEILCLRSFPQLKLTFDEYRNISQKDIVDSIKGELSGHFEDLL
LAIVNCVRNTPAFLAERLHRALKGIGTDEFTLNRIMVSRSEIDLLDIRTEFKKHYGYSLY
SAIKSDTSGDYEITLLKICGGDD

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Inhibitor of phospholipase A2, also possesses anti- coagulant properties. Also cleaves the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate

# Drug_Target_2_SwissProt_ID:
P12429

# Drug_Target_2_SwissProt_Name:
ANXA3_HUMAN

# Drug_Target_2_Synonyms:
35-alpha calcimedin
Annexin III
Inositol 1,2-cyclic phosphate 2-phosphohydrolase
Lipocortin III
PAP-III
Placental anticoagulant protein III

# Drug_Target_2_Theoretical_pI:
5.71

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB03994
